Overview of Dr. Venugopal
Dr. Parameswaran Venugopal is a hematologist in Chicago, IL and is affiliated with multiple hospitals in the area, including Rush University Medical Center and Rush Oak Park Hospital. He received his medical degree from University of Kerala Medical College and has been in practice 41 years. He specializes in hematologic oncology and is experienced in hematologic oncology.
Office
1725 West Harrison Street, Suite 809.
Chicago, IL 60612Fax+1 312-942-3192
Education & Training
- Rush University Medical CenterFellowship, Hematology and Medical Oncology, 1994 - 1996
- Rush University Medical CenterResidency, Internal Medicine, 1993 - 1994
- Henry Ford Health/Henry Ford HospitalInternship, Internal Medicine, 1992 - 1993
- University of LondonDiploma, Clinical Pathology, 1989
- Henry Ford Health/Henry Ford HospitalResidency, Internal Medicine, 1976 - 1979
- Rush University Medical CenterResidency, Internal Medicine, 1979
- University of Kerala Medical CollegeClass of 1977
Certifications & Licensure
- IL State Medical License 1994 - 2026
- MI State Medical License 1992 - 1993
- National Board of Physicians and Surgeons Hematology
- National Board of Physicians and Surgeons Internal Medicine
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013
- “Honored Hematologist” Award Leukemia Lymphoma Society, 2012
- “Hero of Hope” Leukemia Research Foundation, 2012
- Join now to see all
Clinical Trials
- Efficacy Study of Oral Sapacitabine to Treat Acute Myeloid Leukemia in Elderly Patients Start of enrollment: 2007 Dec 01
- A Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia Start of enrollment: 2011 Oct 01
Publications & Presentations
PubMed
- Acalabrutinib alone or in combination with rituximab for follicular lymphoma: An open-label study.Paolo Strati, Rebecca Champion, Morton Coleman, Sonali M Smith, Parameswaran Venugopal
British Journal of Haematology. 2024-12-01 - 3 citationsParsaclisib, a PI3Kδ inhibitor, in relapsed and refractory mantle cell lymphoma (CITADEL-205): a phase 2 study.Pier Luigi Zinzani, Marek Trněný, Vincent Ribrag, Vittorio Ruggero Zilioli, Jan Walewski
Eclinicalmedicine. 2023-08-01 - 12 citationsOlder patients with primary central nervous system lymphoma: Survival and prognostication across 20 U.S. cancer centers.Kevin A David, Suchitra Sundaram, Seo-Hyun Kim, Ryan Vaca, Yong Lin
American Journal of Hematology. 2023-06-01
Journal Articles
- The Present and Future Cardiovascular Medicine and Society the Cardiologist and the Cancer Patient: Challenges to Cardio-Oncology (Or Onco-Cardiology) and Call to ActionAgne Paner, Hena Patel, Timothy Kuzel, Parameswaran Venugopal, Tochi M Okwuosa, Nicole Prabhu, Kim A Williams, ScienceDirect
- Impact of Insulin-Like Growth Factor-1 & Insulin-Like Growth Factor Binding Protiens On Outcomes in Acute Myeloid LeukemiaKarmali, Reem; Larson, Melissa L; Shammo, Jamile; Basu, Sanjib; Christopherson, Kent W; Borgia, Jeffery A; Venugopal, Parameswaran, Leukemia & Lymphoma, 1/1/2015
- A phase III open label randomized study of cytarabine in comibination with amonafide L-malate or daunorubicin as inducation therapy for patients with secondary acute ...Richard Stone, Emmanuele Mazola, Steven L Allen, Arnaud Pigneux, Robert K. Stuart, Meir Wetzler, David Rizzieri, Harry Paul Erba, Lloyd Damon, Junho Jang, Martin S. Ta..., Journal of Clinical Oncology, 1/1/2015
- Join now to see all
Books/Book Chapters
Abstracts/Posters
- The Evaluation and Treatment (Tx) of Burkitt Lymphoma (BL) in the Modern Era: Real World (RW) Outcomes and Prognostication across 26 US Cancer Centers (CC)Parameswaran Venugopal, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Outcomes of Patients with Newly-Diagnosed Burkitt Lymphoma (BL) and Central Nervous System (CNS) Involvement Treated in the Modern Era: A Multi-Institutional Real-Worl...Parameswaran Venugopal, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Marked lymphocytosis in Hairy Cell Leukemia: Need for caution when diagnosing Variant Hairy Cell LeukemiaSahr Syed, Jason Macklis, Parameswaran Venugopal, Brett Mahon, CAP’15 meeting, Nashville, TN, 1/7/2015
- Join now to see all
Lectures
- Copanlisib for Follicular Lymphoma. FDA Approvals and Their Incorporation into Clinical Practice2018 ASCO Annual Meeting - Chicago, Illinois - 06/1/2018
- Management of High Risk Aggressive LymphomaCoeur d'alene, ID - 1/28/2015
- Hodgkin Lymphoma, management1/26/2015
- Join now to see all
Press Mentions
- Nurse Rescues Stranger in Fiery WreckMay 11th, 2022
- Lessons Learned About Dying from a Dying Son, on World Cancer Day 2020January 30th, 2020
- Novel Agents Strengthen Treatment Armamentarium in Non-Hodgkin LymphomaJanuary 3rd, 2020
Professional Memberships
- Member
- Fellow
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: